Eton Pharmaceuticals (ETON) Expected to Announce Quarterly Earnings on Thursday

Eton Pharmaceuticals (NASDAQ:ETON) is expected to be issuing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of $0.3125 per share and revenue of $41.97 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings results on Thursday, August 13th. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.19 by $0.24. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. The company had revenue of $37.59 million during the quarter, compared to the consensus estimate of $27.11 million. On average, analysts expect Eton Pharmaceuticals to post $1.13 EPS for the current fiscal year and $1.94 EPS for the next fiscal year.

Eton Pharmaceuticals Trading Up 0.3%

ETON opened at $50.95 on Wednesday. Eton Pharmaceuticals has a one year low of $14.27 and a one year high of $66.37. The company has a market cap of $1.46 billion, a P/E ratio of 134.08 and a beta of 0.89. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.30 and a current ratio of 1.52. The business’s 50-day simple moving average is $55.48 and its 200-day simple moving average is $35.92.

Analysts Set New Price Targets

ETON has been the subject of a number of research analyst reports. B. Riley Financial reaffirmed a “buy” rating and issued a $70.00 price target (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. Weiss Ratings upgraded shares of Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Tuesday, September 22nd. Zacks Research raised shares of Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 12th. Canaccord Genuity Group boosted their price objective on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a “buy” rating in a research report on Friday, August 14th. Finally, HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of Eton Pharmaceuticals in a research report on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Eton Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $71.50.

Insider Transactions at Eton Pharmaceuticals

In other news, Director Paul V. Maier sold 50,000 shares of Eton Pharmaceuticals stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the sale, the director owned 59,745 shares in the company, valued at approximately $3,529,137.15. The trade was a 45.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Krempa sold 4,166 shares of the business’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $55.07, for a total value of $229,421.62. Following the completion of the sale, the insider directly owned 43,381 shares of the company’s stock, valued at $2,388,991.67. The trade was a 8.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 79,166 shares of company stock worth $4,809,672 in the last quarter. Insiders own 16.49% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.